Forum for Science, Industry and Business

Sponsored by:     3M 
Search our Site:

 

Study predicts hepatitis C will become a rare disease in 22 years

05.08.2014

Computer simulation forecasts favorable trends in eradicating hepatitis C

Effective new drugs and screening would make hepatitis C a rare disease by 2036, according to a computer simulation conducted by The University of Texas MD Anderson Cancer Center and the University of Pittsburgh Graduate School of Public Health. The results of the simulation are reported in the August 5 edition of the journal Annals of Internal Medicine.


This is Jagpreet Chhatwal, Ph.D., University of Texas M. D. Anderson Cancer Center.

Credit: MD Anderson Cancer Center

"Hepatitis C (HCV) is the leading cause of liver cancer and accounts for more than 15,000 deaths in the U.S. each year," said Jagpreet Chhatwal, Ph.D., assistant professor of Health Services Research at MD Anderson, and corresponding author on the study.

"If we can improve access to treatment and incorporate more aggressive screening guidelines, we can reduce the number of chronic HCV cases, prevent more cases of liver cancer and reduce liver-related deaths," Chhatwal said.

HCV – a virus transmitted through the blood – is spread by sharing of needles, the use of contaminated medical equipment, and by tattoo and piercing equipment that has not been fully sterilized. Those at the highest risk for exposure are baby boomers – people born between 1945 and 1965. Widespread screening of the U.S. blood supply for hepatitis C began in 1992. A majority of people were infected through blood transfusions or organ transplants before 1992.

... more about:
»Cancer »HCV »Health »blood »infected »liver »therapies

Baby boomers account for 75 percent of the estimated 2.7 to 3.9 million people infected in the United States. Half of people with the virus are not aware they are infected. The Centers for Disease Control and Prevention, and the U.S. Preventive Services Task Force now recommend a one-time HCV screening for this population group.

In this study, Chhatwal and his collaborators used a mathematical model with information from several sources including more than 30 clinical trials to predict the impact of new therapies called "direct-acting antivirals" and the use of screening for chronic HCV cases.

Researchers developed a computer model to analyze and predict disease trends from 2001 to 2050. The model was validated with historical data including a recently published national survey on HCV prevalence. Researchers predicted with new screening guidelines and therapies, HCV will only affect one in 1,500 people in the U.S. by 2036.

The model predicts one-time HCV screening of baby boomers would help identify 487,000 cases over the next 10 years.

"Though impactful, the new screening guideline does not identity the large number of HCV patients who would progress to advanced disease stages without treatment and could die," Chhatwal said.

"Making hepatitis C a rare disease would be a tremendous, life-saving accomplishment," said lead author Mina Kabiri, a doctoral student at the University of Pittsburgh Graduate School of Public Health. "However, to do this, we will need improved access to care and increased treatment capacity, primarily in the form of primary care physicians who can manage the care of infected people identified through increased screening."

In this study, researchers predicted a one-time universal screening could identify 933,700 HCV cases. Chhatwal and his colleagues also predict the universal screening and timely treatment can make HCV a rare disease in the next 12 years. Such screening can further prevent:

  • 161,500 liver related deaths,
  • 13,900 liver transplants and
  • 96,300 cases of hepatocellular carcinoma – the most common type of liver cancer. 

Chhatwal, whose current research focuses on evaluations of cancer prevention strategies using quantitative methods, says the availability of highly effective therapies and screening updates provide a great opportunity to tackle the hepatitis C epidemic. "But we need to ensure that we provide timely and affordable access to treatment to achieve the potential benefits."

"The new treatment that costs $1,000 a day has been a subject of debate and can become a barrier to timely access to all patients," Chhatwal said.

"Although recent screening recommendations are helpful in decreasing the chronic HCV infection rates, more aggressive screening recommendations and ongoing therapeutic advances are essential to reducing the burden, preventing liver-related deaths and eventually eradicating HCV," Chhatwal said.

###

The National Institutes of Health (KL2TR000146) funded this research.

Other researchers contributing to this study include Mark Roberts, M.D. of the University of Pittsburgh Graduate School of Public Health; Alison Jazwinski, M.D. of the University of Pittsburgh Medical Center, and Andrew Schaefer, Ph.D. of University of Pittsburgh Swanson School of Engineering.

Katrina Burton | Eurek Alert!
Further information:
http://www.mdanderson.org/

Further reports about: Cancer HCV Health blood infected liver therapies

More articles from Health and Medicine:

nachricht Team discovers how bacteria exploit a chink in the body's armor
20.01.2017 | University of Illinois at Urbana-Champaign

nachricht Rabies viruses reveal wiring in transparent brains
19.01.2017 | Rheinische Friedrich-Wilhelms-Universität Bonn

All articles from Health and Medicine >>>

The most recent press releases about innovation >>>

Die letzten 5 Focus-News des innovations-reports im Überblick:

Im Focus: Traffic jam in empty space

New success for Konstanz physicists in studying the quantum vacuum

An important step towards a completely new experimental access to quantum physics has been made at University of Konstanz. The team of scientists headed by...

Im Focus: How gut bacteria can make us ill

HZI researchers decipher infection mechanisms of Yersinia and immune responses of the host

Yersiniae cause severe intestinal infections. Studies using Yersinia pseudotuberculosis as a model organism aim to elucidate the infection mechanisms of these...

Im Focus: Interfacial Superconductivity: Magnetic and superconducting order revealed simultaneously

Researchers from the University of Hamburg in Germany, in collaboration with colleagues from the University of Aarhus in Denmark, have synthesized a new superconducting material by growing a few layers of an antiferromagnetic transition-metal chalcogenide on a bismuth-based topological insulator, both being non-superconducting materials.

While superconductivity and magnetism are generally believed to be mutually exclusive, surprisingly, in this new material, superconducting correlations...

Im Focus: Studying fundamental particles in materials

Laser-driving of semimetals allows creating novel quasiparticle states within condensed matter systems and switching between different states on ultrafast time scales

Studying properties of fundamental particles in condensed matter systems is a promising approach to quantum field theory. Quasiparticles offer the opportunity...

Im Focus: Designing Architecture with Solar Building Envelopes

Among the general public, solar thermal energy is currently associated with dark blue, rectangular collectors on building roofs. Technologies are needed for aesthetically high quality architecture which offer the architect more room for manoeuvre when it comes to low- and plus-energy buildings. With the “ArKol” project, researchers at Fraunhofer ISE together with partners are currently developing two façade collectors for solar thermal energy generation, which permit a high degree of design flexibility: a strip collector for opaque façade sections and a solar thermal blind for transparent sections. The current state of the two developments will be presented at the BAU 2017 trade fair.

As part of the “ArKol – development of architecturally highly integrated façade collectors with heat pipes” project, Fraunhofer ISE together with its partners...

All Focus news of the innovation-report >>>

Anzeige

Anzeige

Event News

Sustainable Water use in Agriculture in Eastern Europe and Central Asia

19.01.2017 | Event News

12V, 48V, high-voltage – trends in E/E automotive architecture

10.01.2017 | Event News

2nd Conference on Non-Textual Information on 10 and 11 May 2017 in Hannover

09.01.2017 | Event News

 
Latest News

Helmholtz International Fellow Award for Sarah Amalia Teichmann

20.01.2017 | Awards Funding

An innovative high-performance material: biofibers made from green lacewing silk

20.01.2017 | Materials Sciences

Ion treatments for cardiac arrhythmia — Non-invasive alternative to catheter-based surgery

20.01.2017 | Life Sciences

VideoLinks
B2B-VideoLinks
More VideoLinks >>>